Program
CRD-4730
A development code.
Its studies are mostly in Heart Failure · Tachycardia, Ventricular · Heart Defects, Congenital, led by Cardurion Pharmaceuticals.
Furthest: phase 2, since Aug 8, 20233 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cardurion Pharmaceuticals | 32 open or running | phase 2since Aug 8, 2023 | Aug 8, 2023 | Apr 2027phase 2 · NCT06658899 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 8, 2023First study: phase 2 study in Heart Defects, CongenitalFirst studyNCT06005428 · 7 enrolled · United States, Canada, France and more
- Oct 23, 2024Phase 2 study in Polymorphic Catecholaminergic Ventricular TachycardiaNCT06658899 · 12 planned · United States, Canada, France and more
- Jul 17, 2026Phase 2 study in Heart FailureNCT07750873 · 525 planned · United States
Ahead
- Apr 2027Primary completion: phase 2 study in Polymorphic Catecholaminergic Ventricular TachycardiaNCT06658899
- Sep 2028Primary completion: phase 2 study in Heart FailureNCT07750873
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07750873Heart Failure · United States | 2 | Recruiting | Sep 2028 | 525 |
| NCT06658899Polymorphic Catecholaminergic Ventricular Tachycardia · United States, Canada, France and more | 2 | Recruiting | Apr 2027 | 12 |
| NCT06005428Heart Defects, Congenital · United States, Canada, France and more | 2 | Terminated | May 31, 2025 | 7 |
How it is read
Names in the registry
- “CRD-4730”, 3 entries
Codes read as this program: CRD4730.
Conditions, from the studies’ own filings
- Heart Failure, 1 study
- Tachycardia, Ventricular, 1 study
- Heart Defects, Congenital, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.